Publication:
Inhaled budesonide aerosols in treatment of childhood asthma

Simple item page
dc.contributor.authorP. Phanichyakarnen_US
dc.contributor.authorE. C.K. Wongen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-14T09:07:47Z
dc.date.available2018-06-14T09:07:47Z
dc.date.issued1988-12-01en_US
dc.description.abstractTwenty-six children with chronic bronchial asthma, 19 boys and 7 girls, aged between 6 and 16 years with duration of asthma ranging from 1-12 years, were studied by a control, oral prednisolone 5 mg twice a day and inhaled budesonide 200 μg twice daily, each for 3 weeks. The clinical efficacy assessed daily by day and night symptom scores of cough, wheeze, sleep disturbance, limitation of activity, symptomatic inhaled terbutaline usage, daily morning and afternoon Peak Expiratory Flow Rate (PEFR), and weekly PEFR and Forced Expiratory Volume in 1 second (FEV 1 ) in percent of predict, showed statistically significant improvement during the inhaled budesonide aerosol and oral prednisolone treatment periods in comparison with the control. No side effect was observed during any study periods.en_US
dc.identifier.citationAsian Pacific Journal of Allergy and Immunology. Vol.6, No.2 (1988), 111-115en_US
dc.identifier.issn0125877Xen_US
dc.identifier.other2-s2.0-0024209673en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/15553
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0024209673&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleInhaled budesonide aerosols in treatment of childhood asthmaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0024209673&origin=inwarden_US

Files

Collections

Scopus 1969-1990